[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"platinum-sensitive-ovarian-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:platinum-sensitive-ovarian-cancer":138},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,66,95,124,153],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100636319","phase-3-study-to-assess-the-efficacy-and-safety-of-rina-s-with-or-without-bevacizumab-compared-to-investigators-choice-of-platinum-based-chemotherapy-with-or-without-bevacizumab-as-second-line-treatment-in-participants-with-recurrent-platinum-sensitive-ovarian-cancer-100636319",false,"NCT07564141","Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer","A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer","RAINFOL™-07","Key Inclusion Criteria:\n\n* Participant must have histologically confirmed high-grade serous or endometrioid epithelial ovarian cancer (EOC), including primary peritoneal or fallopian tube cancer.\n* Participant must have documented recurrence or progression after first-line (1L) platinum-based chemotherapy regimen (carboplatin + paclitaxel ≥ 4 cycles) with or without bevacizumab and have platinum-sensitive disease defined as radiographic progression at least 6 months (ie, \\>183 days) after their last dose administration of platinum-based therapy.\n* Prior poly (ADP-ribose) polymerase inhibitor(s) (PARPi) maintenance therapy (alone or in combination with bevacizumab) is required for participants with breast cancer susceptibility gene (BRCA 1- and BRCA 2)-mutated (germline or somatic) or homologous recombination deficiency (HRD)-positive disease.\n* Participants must have measurable disease per RECIST v1.1 by investigator at baseline.\n* All participants must provide a tumor specimen.\n* Participants must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at baseline.\n\nKey Exclusion Criteria:\n\n* Participants with clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, or low-grade\u002Fborderline ovarian tumors.\n* Participant has received previous therapy with other anti-angiogenetic agents different from bevacizumab or biosimilar.\n* Participant has received prior therapy with an antibody-drug conjugate (ADC) containing a topoisomerase-1 inhibitor.\n* Participant has received prior therapy with an ADC targeting folate receptor alpha (FRα).\n\nNote: Other protocol-defined Inclusion and Exclusion criteria may apply.","FEMALE","18 Years",{"count":20,"type":21},688,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This Phase 3 study will be conducted in different countries around the world with up to about 688 participants.\n\nThe purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with or without bevacizumab and how it compares to an investigator's choice of platinum-based chemotherapy with or without bevacizumab.\n\nParticipants will receive either:\n\n* Rina-S monotherapy (by itself),\n* Rina-S plus bevacizumab,\n* investigator's choice chemotherapy (by itself) (standard of care), or\n* investigator's choice chemotherapy plus bevacizumab (standard of care).\n\nNo participants will be given placebo. Participants will participate in 1 of 2 arms.\n\nThe treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open.\n\nParticipants will be asked to attend 1 to 3 visits at the study clinic for each cycle (duration of cycle is 3 or 4 weeks, depending on medication received). During visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity and imaging) to monitor whether the study treatment is safe and effective.\n\nThe overall study duration (including screening, treatment, and follow-up) will be different for every participant.",[27,28],"Platinum-Sensitive Ovarian Cancer","Ovarian Cancer","NOT_YET_RECRUITING","2026-06-01",{"date":32,"type":33},"2026-06-03","ACTUAL",{"date":35,"type":21},"2026-07",{"date":37,"type":21},"2031-11",{"name":39,"class":40},"Genmab","INDUSTRY",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100610260","phase-3-study-to-assess-the-efficacy-and-safety-of-rina-s-plus-standard-of-care-compared-to-standard-of-care-for-maintenance-treatment-of-participants-with-recurrent-platinum-sensitive-ovarian-cancer-after-second-line-2l-platinum-based-doublet-chemotherapy-100610260","NCT07225270","Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy","A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)","RAINFOL-04","Key Inclusion Criteria:\n\n* Must have histologically or cytologically confirmed high-grade serous or endometrioid epithelial ovarian cancer (EOC), primary peritoneal cancer, or fallopian tube cancer.\n* Must have PSOC defined as progressive disease \\> 6 months (ie, 183 days) from the last dose of primary (first-line \\[1L\\]) platinum therapy.\n* Participants with known breast cancer (BRCA)-mutated (somatic or germline) or homologous recombination deficiency (HRD)-positive ovarian cancer who achieved complete response (CR)\u002Fno clinical evidence of disease (NED) or partial response (PR) following 1L platinum-based chemotherapy regimen must have previously received PARPi maintenance therapy as part of their 1L treatment.\n* Must have completed platinum-based chemotherapy in the 2L treatment for recurrent PSOC.\n* Must be randomized no later than 8 weeks from the last dose of the 2L platinum-based therapy.\n* Participants must have achieved a CR\u002FNED, PR; or SD permitted only if bevacizumab was given in 2L in combination with platinum-based chemotherapy, as assessed by the investigator, following completion of 2L platinum-based chemotherapy.\n\nKey Exclusion Criteria:\n\n* Participants with clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, or low-grade\u002Fborderline ovarian tumors\n* More than 2 prior lines of systemic therapy.\n* Progression while on or following 2L platinum-based regimen prior to randomization.\n* Participants who receive an intervening systemic anticancer treatment (excluding bevacizumab) after the last dose of 2L platinum-based chemotherapy and prior to randomization.\n\nNote: Other protocol-defined Inclusion and Exclusion criteria may apply.","ALL",{"count":51,"type":21},528,[24],"This Phase 3 study will be conducted in different countries around the world with up to about 528 participants.\n\nThe purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with available standard of care therapy that is already approved and used for ovarian cancer.\n\nParticipants will receive either Rina-S monotherapy (by itself), Rina-S plus bevacizumab, bevacizumab (standard of care) by itself, or no treatment (only monitoring, also standard of care). No participants will be given placebo. Participants will participate in 1 of 2 arms.\n\nThe treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open.\n\nParticipants will be asked to attend 1 to 3 visits at the study clinic for each cycle (duration of cycle is 3 weeks). During visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity and imaging) to monitor whether the study treatment is safe and effective. The overall study duration (including screening, treatment, and follow-up) for each participant will be different for every participant.",[28,55,56],"Platinum-sensitive Ovarian Cancer","PSOC","RECRUITING",{"date":59,"type":33},"2026-06-02",{"date":61,"type":33},"2026-04-03",{"date":63,"type":21},"2030-04",{"name":39,"class":40},13,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100594848","phase-2-a-study-to-assess-change-in-disease-activity-and-adverse-events-in-adult-participants-with-gynecologic-cancers-receiving-intravenous-infusion-of-imgn151-as-monotherapy-or-in-combination-with-other-therapies-100594848","NCT07024784","A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies","A Phase 1b Dose Escalation and Expansion Study of IMGN151 as Monotherapy and in Combination With Other Anti-Cancer Therapies in Subjects With Gynecologic Cancers","Inclusion Criteria:\n\n* ECOG performance status of 0 or 1\n* Participants (except for platinum-sensitive ovarian, fallopian tube, and primary peritoneal cancer (PSOC) participants without disease progression after platinum combination standard of care therapy in Arms B and D) will have ≥ 1 lesion that meets the definition of measurable disease by RECIST v1.1 (radiographically measured by the investigator).\n* Participants will have high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC).\n* Participant has completed prior therapy within the specified times below:\n\n  * Systemic antineoplastic therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of IMGN151.\n  * Focal radiation completed ≥ 2 weeks prior to the first dose of study treatment.\n\nExclusion Criteria:\n\n* Participants with ovarian cancer with histologies including: endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, as well a low-grade or borderline ovarian tumor.\n* History of clinically significant medical conditions or any other reason that the investigator determines would interfere with the participant's participation in this study or would make the participant an unsuitable candidate to receive study treatment.\n* Prior treatment with FRα-targeting therapy.\n* Prior wide-field radiotherapy affecting more than 20% of the bone marrow.",{"count":74,"type":21},377,[76],"PHASE2","Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies in adult participants with gynecologic cancers.\n\nIMGN151 is an investigational drug being developed for the treatment of gynecologic cancers. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. Around 377 participants with gynecologic cancers will be enrolled in the study at approximately 50 sites worldwide.\n\nParticipants will receive intravenous infusions of IMGN151 as monotherapy or in combination with anti-cancer therapies according to their assigned study arm. In Arm A, participants will receive IMGN151 in combination with carboplatin on Day 1 of each cycle. In Arm B, participants will receive IMGN151 in combination with olaparib, twice a day (BID) on Day 1 of each cycle. In Arm C, participants will receive IMGN151 in combination with bevacizumab on Day 1 of each cycle. In Arm D, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm E, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm F, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. The total study duration will be approximately 3 years.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.",[79,27,80,81],"Gynecologic Cancers","Fallopian Tube Cancer","Primary Peritoneal Cancer (PSOC)",[79,27,83,80,81,84,85],"Platinum-Resistant Ovarian Cancer","Cancer","IMGN151","2026-05-29",{"date":59,"type":33},{"date":89,"type":33},"2025-07-30",{"date":91,"type":21},"2028-02",{"name":93,"class":40},"AbbVie",16,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":4},"100627852","phase-2-iparomlimabtuvonralimab--standard-chemotherapy-and-olaparib-in-platinum-sensitive-recurrent-ovarian-cancer-100627852","NCT07454018","Iparomlimab\u002FTuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer","A Single-Arm, Exploratory, Multicenter Study Evaluating Iparomlimab\u002FTuvonralimab Combined With Standard Chemotherapy Followed by Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer","Inclusion Criteria:\n\n1. Female participants aged 18 to 75 years. Voluntarily provide written informed consent and able to comply with protocol requirements.\n2. Histologically and\u002For cytologically confirmed recurrent non-mucinous epithelial ovarian cancer (including serous carcinoma, clear cell carcinoma, endometrioid carcinoma, and carcinosarcoma).\n3. First or second recurrence after standard platinum-containing chemotherapy, with recurrence diagnosed ≥ 6 months after the last dose of platinum-containing chemotherapy (platinum-sensitive recurrence).\n4. Not suitable for surgery as assessed by the investigator.\n5. At least one measurable lesion per RECIST v1.1.\n6. ECOG performance status 0-1.\n7. If no prior BRCA1\u002F2 mutation test result is available, willing to provide tumor tissue and\u002For peripheral blood for confirmation of BRCA status (archival or fresh tumor tissue preferred; if re-biopsy poses safety risk, may be discussed with medical monitor).\n8. Prior exposure to PARP inhibitor(s) other than olaparib is allowed only if the prior PARPi exposure after first-line therapy was \\>18 months for BRCA-mutated participants or \\>12 months for BRCA wild-type participants, and recurrence occurred ≥12 months after the last PARPi dose.\n9. Estimated life expectancy ≥ 3 months.\n10. Adequate organ function: ANC ≥1.5×10\\^9\u002FL; platelets ≥100×10\\^9\u002FL; hemoglobin ≥90 g\u002FL; serum albumin ≥30 g\u002FL; TSH ≤1×ULN (if abnormal, FT3\u002FFT4 within normal range); total bilirubin ≤1.5×ULN; AST\u002FALT ≤2.5×ULN (≤5×ULN if liver metastases); ALP ≤2.5×ULN; serum creatinine ≤1.5×ULN; INR ≤1.5 (if not on anticoagulation).\n11. Women of childbearing potential must have a negative serum\u002Furine pregnancy test within 7 days prior to first dose, must not be breastfeeding, and must use medically accepted contraception during study treatment and for 3 months after the end of study treatment.\n\nExclusion Criteria:\n\n1. Any active autoimmune disease or history of autoimmune disease.\n2. Mucinous ovarian cancer, sex cord-stromal tumors, or other non-eligible histologic types.\n3. Uncontrolled pleural effusion, pericardial effusion, or ascites that cannot be stabilized despite repeated drainage or other interventions per investigator judgment.\n4. Other active malignancy within 2 years prior to first dose.\n5. Central nervous system metastases or carcinomatous meningitis.\n6. Palliative radiotherapy or immunomodulatory agents (e.g., thymosin, interferon, IL-2) or antitumor Chinese patent medicines within 2 weeks prior to first dose; hormonal therapy within 1 week prior to first dose.\n7. Use of immunosuppressive agents or systemic corticosteroids for immunosuppression (prednisone \\>10 mg\u002Fday or equivalent) within 2 weeks prior to enrollment.\n8. Prior immuno-oncology therapies targeting tumor immunity (e.g., PD-1\u002FPD-L1\u002FCTLA-4 inhibitors, immune checkpoint agonists such as ICOS\u002FCD40\u002FCD137\u002FGITR\u002FOX40 antibodies, or immune cell therapy).\n9. Prior treatment with olaparib.\n10. Concomitant use of strong\u002Fmoderate CYP3A inhibitors (washout 2 weeks) or strong\u002Fmoderate CYP3A inducers (washout 5 weeks for enzalutamide\u002Fphenobarbital; 3 weeks for others).\n11. Major surgery, open biopsy, or significant traumatic injury within 4 weeks prior to first dose (except secondary cytoreductive surgery), or planned major elective surgery during the study.\n12. Live vaccine within 4 weeks prior to first dose or planned live vaccination during the study.\n13. Known primary or secondary immunodeficiency, including HIV antibody positive. Untreated chronic hepatitis B or HBV carrier with HBV DNA \\>1000 IU\u002FmL; active hepatitis C.\n14. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n15. History of interstitial lung disease or non-infectious pneumonitis.\n16. Serious infection within 4 weeks prior to first dose (e.g., sepsis, severe pneumonia, or infections requiring hospitalization).\n17. Active or clinically significant inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, chronic diarrhea requiring treatment).\n18. Severe cardiovascular or cerebrovascular disease\u002Fhistory.\n19. Peripheral neuropathy ≥ Grade 2 per NCI CTCAE v5.0.\n20. History of severe hypersensitivity reaction to other monoclonal antibodies. Pregnant or breastfeeding.\n21. Known allergy to any component of QL1706, olaparib, carboplatin, or paclitaxel formulations.\n22. Participation in another investigational drug\u002Fdevice study within 4 weeks prior to first dose.\n23. Any condition that, in the investigator's opinion, would increase risk with study treatment or interfere with study assessments or interpretation.","75 Years",{"count":104,"type":21},45,[76],"This is a prospective, open-label, single-arm, multicenter exploratory clinical study designed to evaluate the efficacy and safety of iparomlimab\u002Ftuvonralimab (QL1706), a bispecific antibody targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), in combination with standard platinum-based chemotherapy followed by olaparib in patients with platinum-sensitive recurrent epithelial ovarian cancer.\n\nEligible participants are women aged 18-75 years with histologically or cytologically confirmed non-mucinous epithelial ovarian cancer (including serous carcinoma, clear cell carcinoma, endometrioid carcinoma, and carcinosarcoma) who experience first or second recurrence at least 6 months after the last platinum-containing chemotherapy, have measurable disease per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1), an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1, and are deemed not suitable for surgery by the investigator.\n\nThe study consists of a screening period (up to 28 days), a treatment period, and a follow-up period. Treatment is administered in 3-week cycles and continues until disease progression, unacceptable toxicity, withdrawal of consent, loss of clinical benefit per investigator judgment, completion of 2 years of iparomlimab\u002Ftuvonralimab (QL1706), or other protocol-defined reasons. Safety assessments are performed regularly during treatment; a safety follow-up visit is conducted 30 (±7) days after the last dose, and survival follow-up is performed every 2 months thereafter. The primary objective is to explore the antitumor efficacy of the regimen in platinum-sensitive recurrent epithelial ovarian cancer, and the secondary objective is to characterize the safety profile of the combination strategy.",[108,55],"Recurrent Ovarian Cancer",[110,111,112,113],"Iparomlimab","Tuvonralimab","Epithelial ovarian cancer","Maintenance therapy","2026-03-05",{"date":116,"type":33},"2026-03-06",{"date":118,"type":21},"2026-03-01",{"date":120,"type":21},"2029-12-31",{"name":122,"class":123},"The First Affiliated Hospital of Soochow University","OTHER",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":131,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":139,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":4},"100615632","phase-2-rescue-study-recurrent-ovarian-cancer-secondary-cytoreduction-using-chemotherapy-response-100615632","NCT07295132","RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)","A Randomized Clinical Trial Evaluating the Role of Secondary Cytoreductive Surgery Following Neoadjuvant Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: Patient Selection Informed by CA-125 Response Dynamics During Chemotherapy (RESCUE Study)","Inclusion Criteria:\n\n* First recurrence of platinum-sensitive, invasive epithelial ovarian, fallopian tube, or primary peritoneal cancer, regardless of initial stage.\n* A progression-free interval of at least 6 months after the end of the last platinum-containing regimen.\n* Demonstrated response during neoadjuvant chemotherapy after recurrence (Complete Response\u002FPartial Response\u002FStable Disease according to RECIST 1.1 or GCIG CA-125 response, which is a ≥50% reduction in pre-treatment CA-125 level sustained for ≥28 days).\n* Women aged 19 years or older.\n* The tumor is judged to be completely resectable by surgery (R0) based on the judgment of an experienced surgeon\n* Patients who provide signed and written informed consent and consent to data transfer and processing.\n\nExclusion Criteria:\n\n* Patients without recurrence\n* Patients with non-epithelial tumors or borderline tumors.\n* Patients with second, third, or subsequent recurrence.\n* Patients with a secondary malignancy treated with laparotomy and other neoplasms, where the treatment is expected to interfere with the treatment of recurrent ovarian cancer or significantly affect prognosis.\n* Patients with platinum-refractory tumors (i.e., progression during chemotherapy or recurrence within 6 months after the end of the previous first platinum-containing regimen).\n* Cases where only palliative surgery is planned.\n* Radiological signs suggestive of metastasis that are considered completely unresectable.\n* Any comorbidity that precludes surgery and\u002For chemotherapy (e.g., poor general condition, severe infection, conditions that may cause severe bleeding, severe renal disease, etc.).\n* Any medical history that may cause excessive surgical risk pre- or post-operatively.\n* Medications being taken that pose a significant surgical risk (e.g., oral anticoagulants, bleeding risk due to bevacizumab).\n* Absence of evaluable archived tumor tissue.","19 Years",{"count":133,"type":21},160,[76],"This is a multicenter, prospective, randomized, open-label Phase III clinical trial (RESCUE study) evaluating the efficacy of secondary cytoreductive surgery (SCS) in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have shown a favorable response to 3-4 cycles of platinum-based neoadjuvant chemotherapy and are assessed as highly likely to achieve complete tumor resection based on selection models. Eligible patients will be randomly assigned to either the experimental arm, receiving SCS followed by chemotherapy (with or without maintenance), or the active comparator arm, receiving chemotherapy only (with or without maintenance), with the primary objective being to compare the Progression-Free Survival (PFS) between the two groups to determine the additional clinical benefit of SCS in this carefully selected patient population.",[137,138],"Ovarian Cancer Recurrent","Platinum Sensitive Ovarian Cancer",[140,141,142,143],"platinum sensitive recurrent ovarian cancer","secondary cytoreductive surgery","neoadjuvant chemotherapy","CA-125 response","2025-12-16",{"date":146,"type":33},"2025-12-19",{"date":148,"type":21},"2025-12-15",{"date":150,"type":21},"2029-11-15",{"name":152,"class":123},"Asan Medical Center",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":165,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":180},"100568807","phase-2-combination-therapy-of-ak112-with-chemotherapy-andor-olaparib-in-platinum-sensitive-ovarian-cancer-100568807","NCT06686030","Combination Therapy of AK112 With Chemotherapy and\u002For Olaparib in Platinum-sensitive Ovarian Cancer","An Exploratory, Multi-cohort Phase II Study of Combination Therapy of AK112 With Chemotherapy and\u002For Olaparib in Platinum-sensitive Ovarian Cancer","Inclusion Criteria:\n\n1. Signs the written informed consent form.\n2. Female participants who are at least 18 years of age on the day of signing informed consent with.\n3. ECOG of 0 or 1.\n4. Life expectancy ≥3 months.\n5. Histologically documented epithelial and non-mucinous PSOC. PSOC was defined as radiographic progression greater than 6 months from last dose of platinum-based chemotherapy.\n\n   Note:\n   1. If breast cancer susceptibility gene (BRCA) positive participants must have received prior treatment with a poly adenosine phosphate-ribose polymerase inhibitor (PARPi).\n   2. Ovarian cancer includes ovarian cancer, fallopian tube cancer and primary peritoneal cancer in this study, unless otherwise specified.\n6. Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the site study team.\n7. Be able to provide formalin fixed, paraffin-embedded (FFPE) tumor tissue.\n8. Has adequate organ function.\n9. All subjects of reproductive potential must agree to use an effective method of contraception, during and for 6 months after the last dose of study treatment.\n\nExclusion Criteria:\n\n1. Other pathological types such as mucinous cancer, sex cord stromal cell tumor, etc.\n2. Presence of central nervous system (CNS) metastases or carcinomatous meningitis.\n3. Subjects with uncontrollable pleural, pericardial, or peritoneal effusion requiring repeated drainage.\n4. Subjects with other active malignancies within 3 years prior to randomization.\n5. Received systemic anti-tumor therapy within 2 weeks prior to randomization.\n6. Any prior treatments targeting the mechanism of tumor immunity.\n7. Major surgical , open biopsy or significant trauma within 4 weeks prior to randomization; or elective major surgical treatment required during the study.\n8. Active or potentially recurrent autoimmune disease.\n9. Subjects who require systemic treatment with glucocorticoid (\\>10 mg\u002Fday of prednisone or equivalent glucocorticoid) or other immunosuppressive agents within 14 days prior to randomization.\n10. Receiving live vaccines within 4 weeks prior to randomization.\n11. Known primary or secondary immunodeficiencies, including testing positive for human immunodeficiency virus (HIV) antibodies.\n12. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.\n13. Known history of interstitial lung disease or non-infectious pneumonitis.\n14. Serious infections requiring hospitalization.\n15. Presence of active infection requiring systemic therapy.\n16. Subjects with active hepatitis B and active viral hepatitis C.\n17. Active or documented inflammatory bowel diseases, active diverticulitis.\n18. Subjects with clinically significant cardio-cerebrovascular disease.\n19. Unresolved toxicities from prior anticancer therapy.\n20. History of severe hypersensitivity reactions to other mAbs.\n21. Pregnant or lactating women.\n22. Any condition that, in the opinion of the Investigator, may result in a risk when receiving the study drug.\n23. Exclusion Criteria for combination therapy-Related: For cohort 1: Known contraindications or allergy to paclitaxel or carboplatin. For Cohorts 1-10A, Cohort 1-20A, and Cohort 2: Known contraindications or allergy to Olaparib.\n24. Exclusion Criteria for AK112-Related: Known contraindications or allergy to any component of VEGF mABs or any medical conditions that affect the safety of AK112.",{"count":161,"type":21},150,[76],"An Exploratory, Multi-cohort Phase II Study of combination therapy of AK112 with chemotherapy and\u002For olaparib in platinum-sensitive ovarian cancer(PSOC)",[55],[166,167,168,169,170],"platinum-sensitive ovarian cancer","PD-1","VEGF","antibody","AK112","2025-04-11",{"date":173,"type":33},"2025-04-16",{"date":175,"type":33},"2025-02-17",{"date":177,"type":21},"2028-07",{"name":179,"class":40},"Akeso",1]